West Pharm Svcs SEC Filings

West Pharmaceutical Services executive Norman D. Finch, Jr., who serves as SVP, General Counsel & Corporate Secretary, reported equity awards in the company’s stock. On December 8, 2025, he received 192 restricted stock units, each representing a right to receive one share of common stock. This award is scheduled to vest in four equal installments beginning December 8, 2026, providing a staggered long-term incentive.

On the same date, Finch also received a stock option covering 459 shares of West Pharmaceutical common stock at an exercise price of $269.08 per share, with an expiration date of December 8, 2035. Both the RSUs and the option are reported as directly owned and reflect standard equity-based compensation for a senior officer.

West Pharmaceutical Services reported insider equity holdings for a senior executive. The reporting person is an officer of the company, serving as SVP, General Counsel and Corporate Secretary. The filing shows derivative holdings including 192 restricted stock units tied to West Pharmaceutical common stock, which vest in four equal installments beginning on December 8, 2026. It also discloses a stock option covering 459 shares of common stock with an exercise price of $269.08 per share and an expiration date of December 8, 2035. These details outline part of the executive’s long-term, equity-based compensation linked to the company’s share performance.

West Pharmaceutical Services (WST): Schedule 13G/A filed by The Vanguard Group

The Vanguard Group reported beneficial ownership of 9,704,948 shares of WST common stock, representing 13.49% of the class as of 09/30/2025. Vanguard reported 0 shares with sole voting power and 422,261 with shared voting power. It reported 9,018,715 shares with sole dispositive power and 686,233 with shared dispositive power.

Vanguard states the securities are held in the ordinary course and not to influence control. Its clients have the right to receive dividends or sale proceeds, and no single client’s interest exceeds 5%.

West Pharmaceutical Services (WST) reported higher Q3 results. Net sales rose to $804.6 million from $746.9 million, driven primarily by the Proprietary Products segment ($647.5 million vs. $601.4 million). Gross profit increased to $294.3 million, and operating profit was $167.6 million. Net income was $140.0 million, with diluted EPS of $1.92, up from $1.85.

For the first nine months, net sales reached $2,269.1 million versus $2,144.4 million. Operating cash flow was strong at $503.7 million, while capital expenditures were $209.8 million. Cash and cash equivalents were $628.5 million at September 30, 2025, and long-term debt stood at $202.7 million, with $497.7 million available under the $500 million revolver. The company spent $134.0 million on share repurchases year‑to‑date and paid dividends of $45.4 million.

Product mix remained favorable: High‑Value Product components represented 48% of Q3 sales. The company recorded $21.9 million of restructuring and related charges year‑to‑date under a 2025 plan that targets approximately $30–$32 million of total charges and annualized savings of $35–$40 million. The effective tax rate was 19.8% in Q3 and 20.1% year‑to‑date.

West Pharmaceutical Services, Inc. furnished an 8-K announcing its third-quarter 2025 financial results. The company provided a press release and an investor presentation as exhibits.

The materials were furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD). The company noted these items are furnished, not filed, and therefore are not subject to Section 18 liabilities. The press release (Exhibit 99.1) and presentation (Exhibit 99.2) are dated October 23, 2025.

Janet Brutschea Haugen, a director of West Pharmaceutical Services, Inc. (WST), reported transactions dated 09/30/2025. The Form 4 discloses a disposition of 1,319.348 shares of Common Stock and the acquisition of 48 Phantom Stock Units on the same date. The filing shows 162.161 shares reported as beneficially owned following the reported derivative transaction. Footnotes state the 1,071 restricted stock units and dividend equivalents underlying part of the position will vest in full at the next annual shareholder meeting and be distributable under the Deferred Compensation Plan for Outside Directors, and that phantom stock units are settled by delivery of shares upon the reporting person’s termination as a director. The form is signed by an agent on behalf of Ms. Haugen on 10/02/2025.

West Pharmaceutical Services, Inc. files this Form S-8 to register additional employee benefit plan securities and incorporates by reference prior SEC filings, including its Annual Report for the fiscal year ended December 31, 2024 and Quarterly Reports for the quarters ended March 31, 2025 and June 30, 2025. The filing also incorporates Current Reports filed on March 11, 2025; April 14, 2025; April 24, 2025; May 8, 2025 (amended May 12, 2025); and July 21, 2025, plus the description of Common Stock included in Exhibit 4.4 to the 2024 filing.

The company discloses that Ryan Metz, Associate General Counsel, rendered the legal opinion and beneficially owns or has rights to acquire less than 1% of the common stock and is eligible to participate in the 2016 Plan. Article IV of the Bylaws provides indemnification for directors, officers, employees and agents subject to statutory limits, and such indemnification constitutes a contract that cannot be detrimentally amended as to prior acts.

Robert W. McMahon, the company's SVP & Chief Financial Officer, reported an initial beneficial ownership position in West Pharmaceutical Services (WST). He directly holds restricted stock units of 3,168 and 12,670 shares, and two stock options covering 7,647 and 7,137 shares with an exercise price of $240.33. The options become exercisable on 08/11/2026 and expire on 08/11/2035. In total the reported awards underlie 30,622 common shares and are reported as direct beneficial ownership.